Cutera (NASDAQ:CUTR) Now Covered by StockNews.com

StockNews.com started coverage on shares of Cutera (NASDAQ:CUTR) in a report released on Tuesday morning. The firm issued a sell rating on the medical device company’s stock.

Other analysts have also issued reports about the company. Piper Sandler reissued a “neutral” rating and set a $1.00 price objective (down from $3.00) on shares of Cutera in a report on Friday, August 9th. Stephens decreased their price objective on Cutera from $10.00 to $5.00 and set an “overweight” rating for the company in a report on Friday, August 9th.

Cutera Stock Performance

Shares of NASDAQ CUTR opened at $0.49 on Tuesday. The firm’s 50-day simple moving average is $0.58 and its 200 day simple moving average is $1.10. The stock has a market cap of $9.83 million, a price-to-earnings ratio of -0.07 and a beta of 1.35. Cutera has a fifty-two week low of $0.28 and a fifty-two week high of $4.97.

Hedge Funds Weigh In On Cutera

Several institutional investors have recently modified their holdings of CUTR. Bayesian Capital Management LP bought a new position in shares of Cutera in the first quarter valued at approximately $33,000. Ground Swell Capital LLC bought a new position in shares of Cutera in the second quarter valued at approximately $37,000. Squarepoint Ops LLC grew its holdings in shares of Cutera by 164.5% in the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after acquiring an additional 70,870 shares in the last quarter. Finally, Bank of Montreal Can grew its holdings in shares of Cutera by 14.2% in the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after acquiring an additional 35,248 shares in the last quarter. 90.70% of the stock is owned by institutional investors.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.